Homocysteine reduction by B-vitamin supplementation increases t-PA and PAI-1 levels in patients with venous thromboembolism.
Rodrigues
C A
CA
Morelli
V M
VM
DA Silveira
R C
RC
D'Almeida
V
V
Lourenço
D M
DM
D000293:Adolescent; D000328:Adult; D000368:Aged; D019587:Dietary Supplements; D004311:Double-Blind Method; D004338:Drug Combinations; D004730:Endothelium, Vascular / Q000187:drug effects; D005492:Folic Acid / Q000627:therapeutic use; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011655:Pulmonary Embolism / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D011736:Pyridoxine / Q000627:therapeutic use; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000097:blood*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D014805:Vitamin B 12 / Q000627:therapeutic use; D014803:Vitamin B Complex / Q000494:pharmacology / Q000627:therapeutic use*
D004338:Drug Combinations; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D006710:Homocysteine; D014803:Vitamin B Complex; D005492:Folic Acid; D010959:Tissue Plasminogen Activator; D011736:Pyridoxine; D014805:Vitamin B 12